Detail of the clinical trial
| Title of the trial | A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB PLUS TIRAGOLUMAB AND ATEZOLIZUMAB PLUS PLACEBO AS FIRST-LINE TREATMENT IN PATIENTS WITH RECURRENT/METASTATIC PD-L1 POSITIVE SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. |
|---|---|
| EudraCT number | 2020-002852-19 |
| Protocol number | BO42533 |
| Sponsor | F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland |
| Indications | Oncology |
| Diagnosis | CARCINOMA OF THE HEAD AND NECK |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2020 |
| Date of approval by Institute (SÚKL) | 3.3.2021 |
| Date of approval by EC | 4.2.2021 |
| Date of initiation CT in ČR | 16.6.2021 |
| Date of ending CT in ČR | |
| Notice | |
| Sites |
Nemocnice na Bulovce,Ústav radiační onkologie,Budínova 67/2,Praha 8,18000 Masarykův onkologický ústav,Klinika komplexní onkologické péče,Žlutý kopec 543/7,Brno,65653 Fakultní nemocnice v Motole,Onkologická klinika,V Úvalu 84/1,Praha 5,150 06 FN Hradec Králové,Klinika onkologie a radioterapie,Sokolská 581,Hradec Králové,50005 |
cz